ArticleProceedings of the National Academy of Sciences of the United States of America2005
Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 271 citations in OpenAlex.
- Addition of platelet concentrate to dermo-epidermal skin graft in deep burn trauma reduces scarring and need for revision surgeries.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2014Trial
- The molecular mechanisms of platelets in tumor invasion and metastasis: a controversial role.Cancer biology & therapy · 2026Review
- Review
- Dynamic changes in D-dimer during first-line therapy and their association with overall survival in advanced lung cancer: a retrospective study.American journal of cancer research · 2026Article
- Phenotyping of human platelets in response to platelet agonists and inhibitors using multiparameter flow cytometry and unbiased high-dimensional analysis.Research and practice in thrombosis and haemostasis · 2025Article
- Reciprocal tumor-platelet interaction through the EPHB1-EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adenocarcinoma.Cancer communications (London, England) · 2025Article
- Review
- Cancer-Associated Stroke: Thrombosis Mechanism, Diagnosis, Outcome, and Therapeutic Strategies.Journal of stroke · 2024Review
- Platelets regulate ischemia-induced revascularization and angiogenesis by secretion of growth factor-modulating factors.Blood advances · 2023Article
- The critical role of platelet in cancer progression and metastasis.European journal of medical research · 2023Review
- Mechanisms and roles of the first stage of nodule formation in lepidopteran insects.Journal of insect science (Online) · 2023Article
- Platelets and (Lymph)angiogenesis.Cold Spring Harbor perspectives in medicine · 2023Review
- Platelets in the tumor microenvironment and their biological effects on cancer hallmarks.Frontiers in oncology · 2023Review
- Protease-activated receptors in health and disease.Physiological reviews · 2023Review
- Osteogenesis in human periodontal ligament stem cell sheets is enhanced by the protease-activated receptor 1 (PARScientific reports · 2022Article
- Is autologous platelet activation the key step in ovarian therapy for fertility recovery and menopause reversal?BioMedicine · 2022Review
- The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets.Nature communications · 2021Article
- Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TAPs).Cancer immunology, immunotherapy : CII · 2021Review
- Surgical Stress Promotes Tumor Progression: A Focus on the Impact of the Immune Response.Journal of clinical medicine · 2020Review
- Revisiting Platelets and Toll-Like Receptors (TLRs): At the Interface of Vascular Immunity and Thrombosis.International journal of molecular sciences · 2020Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The roles of proteinase-activated receptors (PARs) in platelet functions other than aggregation are not well understood. Among these is the release of factors that regulate the process of angiogenesis, such as endostatin and VEGF, which, respectively, inhibit and promote angiogenesis. PAR1 and PAR4 are expressed on the surface of human platelets and can be activated by thrombin. In the present study, we have attempted to determine the roles of PAR1 and PAR4 in regulating release of endostatin and VEGF from human platelets. Aggregation and endostatin release could be elicited by a specific PAR4 agonist (AYPGKF-NH(2)). The PAR4 agonist concentration dependently suppressed VEGF release. A selective PAR1 agonist (TFLLR-NH(2)) induced platelet aggregation and VEGF release but suppressed endostatin release. Thrombin did not affect endostatin or VEGF release. However, in the presence of a selective PAR1 antagonist (SCH79797), thrombin stimulated endostatin release and suppressed VEGF release. Conversely, in the presence of a selective PAR4 antagonist (transcinnamoyl-YPGKF-NH(2)), thrombin stimulated VEGF release. In vivo, treatment of rats with established gastric ulcers with a PAR1 antagonist each day for 1 wk resulted in a significant retardation of healing. We conclude that PAR1 and PAR4 counter-regulate the release of endostatin and VEGF from platelets. These protease-activated receptors could therefore play a crucial role in regulating angiogenesis and in turn could regulate the processes of wound healing and tumor growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.